Success Metrics

Clinical Success Rate
100.0%

Based on 36 completed trials

Completion Rate
100%(36/36)
Active Trials
0(0%)
Results Posted
17%(6 trials)

Phase Distribution

Ph not_applicable
12
29%
Ph phase_3
14
33%
Ph phase_2
8
19%
Ph phase_1
3
7%
Ph phase_4
5
12%

Phase Distribution

3

Early Stage

8

Mid Stage

19

Late Stage

Phase Distribution42 total trials
Phase 1Safety & dosage
3(7.1%)
Phase 2Efficacy & side effects
8(19.0%)
Phase 3Large-scale testing
14(33.3%)
Phase 4Post-market surveillance
5(11.9%)
N/ANon-phased studies
12(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

97.3%

36 of 37 finished

Non-Completion Rate

2.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

42

all time

Status Distribution
Completed(36)
Terminated(1)
Other(5)

Detailed Status

Completed36
unknown3
Suspended2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
42
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (7.1%)
Phase 28 (19.0%)
Phase 314 (33.3%)
Phase 45 (11.9%)
N/A12 (28.6%)

Trials by Status

withdrawn12%
unknown37%
completed3686%
suspended25%

Recent Activity

Clinical Trials (42)

Showing 20 of 42 trialsScroll for more
NCT00099632Phase 2

Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy

Completed
NCT00270296Phase 2

Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

Completed
NCT00017719Phase 3

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Completed
NCT00086359Phase 3

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

Completed
NCT00000896Not Applicable

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Completed
NCT00000916Phase 2

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

Completed
NCT01352715Phase 3

Study of Options for Second-Line Effective Combination Therapy (SELECT)

Completed
NCT01618305Phase 4

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

Completed
NCT00084136Phase 4

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Completed
NCT02499874Phase 1

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

Completed
NCT02832778Phase 1

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Unknown
NCT00001094Phase 2

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

Withdrawn
NCT00006441Not Applicable

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

Completed
NCT00120510Not Applicable

Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti

Completed
NCT00014014Phase 1

Zidovudine and Lamivudine Given Once Versus Twice Daily

Completed
NCT00100568Not Applicable

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

Completed
NCT00014937Not Applicable

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

Completed
NCT00000919Not Applicable

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed
NCT00000903Phase 3

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

Completed
NCT00000918Phase 2

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Completed

Drug Details

Intervention Type
DRUG
Total Trials
42